Contract to support Phase II river blindness drug trial Antibiotic drug study for the treatment of the second-most common cause of blindness due to infection
Open Orphan PLC (ORPH.L) NEJM Opinion Piece
The New England Journal of Medicine (NEJM) publishes editorial relating to Human Challenge Programme
Poolbeg Pharma PLC (POLB.L) Admission to AIM
First day of trading
Open Orphan PLC (ORPH.L) AIM Schedule 1 update by Poolbeg Pharma plc
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , notes
Open Orphan PLC (ORPH.L) New Contract win for Breda office & COVID-19 Programme update
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces